The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes
Open accessAbstract
Ras-induced malignant transformation requires Ras farnesylation, a lipid posttranslational modification catalyzed by farnesyltransferase (FTase). Inhibitors of this enzyme have been shown to block Ras-dependent transformation, but the mechanism by which this occurs remains largely unknown. We have designed FTI-276, a peptide mimetic of the COOH-terminal Cys-Val-Ile-Met of K-Ras4B that inhibited potently FTase in vitro (IC50 = 500 pM) and was highly selective for FTase over geranylgeranyltransferase I (GGTase I) (IC50 = 50 nM). FTI-277, the methyl ester derivative of FTI-276, was extremely potent (IC50 = 100 nM) at inhibiting H-Ras, but not the geranylgeranylated Rap1A processing in whole cells. Treatment of H-Ras oncogene-transformed NIH 3T3 cells with FTI-277 blocked recruitment to the plasma membrane and subsequent activation of the serine/threonine kinase c-Raf-1 in cells transformed by farnesylated Ras (H-RasF), but not geranylgeranylated, Ras (H-RasGG). FTI-277 induced accumulation of cytoplasmic non-farnesylated H-Ras that was able to bind Raf and form cytoplasmic Ras/Raf complexes in which Raf kinase was not activated. Furthermore, FTI-277 blocked constitutive activation of mitogen-activated protein kinase (MAPK) in H-RasF, but not H-RasGG, or Raf-transformed cells. FTI-277 also inhibited oncogenic K-Ras4B processing and constitutive activation of MAPK, but the concentrations required were 100-fold higher than those needed for H-Ras inhibition. The results demonstrate that FTI-277 blocks Ras oncogenic signaling by accumulating inactive Ras/Raf complexes in the cytoplasm, hence preventing constitutive activation of the MAPK cascade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Barbacid, M. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004023 · Cited by 3,885
All ras proteins are polyisoprenylated but only some are palmitoylated
Hancock, J. F., Magee, A. I., Childs, J. E., & Marshall, C. J. (1989) · Cell · doi:10.1016/0092-8674(89)90054-8 · Cited by 1,799
Hancock, J. F., Paterson, H., & Marshall, C. J. (1990) · Cell · doi:10.1016/0092-8674(90)90294-o · Cited by 1,059
Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane
Leevers, S. J., Paterson, H. F., & Marshall, C. J. (1994) · Nature · doi:10.1038/369411a0 · Cited by 1,011
MAP kinase kinase kinase, MAP kinase kinase and MAP kinase
Marshall, C. J. (1994) · Current Opinion in Genetics & Development · doi:10.1016/0959-437x(94)90095-7 · Cited by 999
Important Advances in Oncology: 1986
Merrill, J. M. (1986) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1986.03380040106043 · Cited by 907
p21ras is modified by a farnesyl isoprenoid.
Casey, P. J., Solski, P. A., Der, C. J., & Buss, J. E. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.21.8323 · Cited by 856
Self-citationInhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides
Reiss, Y., Goldstein, J. L., Seabra, M. C., Casey, P. J., & Brown, M. S. (1990) · Cell · doi:10.1016/0092-8674(90)90242-7 · Cited by 817
Important Advances in Oncology
DeVita, V. T., Hellman, S., & Rosenberg, S. A. (1991) · Anti-Cancer Drugs · doi:10.1097/00001813-199108000-00014 · Cited by 760
Benzodiazepine Peptidomimetics: Potent Inhibitors of Ras Farnesylation In Animal Cells
James, G. L., Goldstein, J. L., Brown, M. S., Rawson, T. E., Somers, T. C., McDowell, R. S., Crowley, C. W., Lucas, B. K., Levinson, A. D., & Marsters, J. C. (1993) · Science · doi:10.1126/science.8316834 · Cited by 630
Cited by
Takai, Y., Sasaki, T., & Matozaki, T. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.1.153 · Cited by 2,475
Luckman, S. P., Hughes, D. E., Coxon, F. P., Russell, R. G. G., & Dr. Rogers, M. J. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.4.581 · Cited by 1,176
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway
Freed-Pastor, W. A., Mizuno, H., Zhao, X., Langerød, A., Moon, S.-H., Rodriguez-Barrueco, R., Barsotti, A., Chicas, A., Li, W., Polotskaia, A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.017 · Cited by 865
The complexity of Raf-1 regulation
Morrison, D. K., & Cutler, R. E. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80060-9 · Cited by 635
Targeting protein prenylation for cancer therapy
Berndt, N., Hamilton, A. D., & Sebti, S. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3151 · Cited by 614
Self-citationRegulating the regulator: post-translational modification of RAS
Ahearn, I. M., Haigis, K., Bar-Sagi, D., & Philips, M. R. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3255 · Cited by 557
Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic Development
Rowinsky, E. K., Windle, J. J., & Von Hoff, D. D. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3631 · Cited by 537
Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
Degirmenci, U., Wang, M., & Hu, J. (2020) · Cells · doi:10.3390/cells9010198 · Cited by 534
The interplay between Src family kinases and receptor tyrosine kinases
Bromann, P. A., Korkaya, H., & Courtneidge, S. A. (2004) · Oncogene · doi:10.1038/sj.onc.1208079 · Cited by 454
The Concise Guide to PHARMACOLOGY 2013/14: Enzymes
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12451 · Cited by 425
Inhibition of Ras for Cancer Treatment: The Search Continues
Baines, A. T., Xu, D., & Der, C. J. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.121 · Cited by 382
Self-citationTargeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
Cox, A. D., Der, C. J., & Philips, M. R. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3214 · Cited by 351
Self-citationDr. Coxon, F. P., Helfrich, M. H., Van't Hof, R., Sebti, S., Ralston, S. H., Hamilton, A., & Rogers, M. J. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.8.1467 · Cited by 361
Self-citationSlevin, M., Kumar, S., & Gaffney, J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109443200 · Cited by 346
A tagging-via-substrate technology for detection and proteomics of farnesylated proteins
Kho, Y., Kim, S. C., Jiang, C., Barma, D., Kwon, S. W., Cheng, J., Jaunbergs, J., Weinbaum, C., Tamanoi, F., Falck, J., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403413101 · Cited by 327
THE POTENTIAL OF FARNESYLTRANSFERASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS
Gibbs, J. B., & Oliff, A. (1997) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.37.1.143 · Cited by 324
Reuter, C. W. M., Morgan, M. A., & Bergmann, L. (2000) · Blood · doi:10.1182/blood.v96.5.1655 · Cited by 300
Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer
Graaf, M. R., Richel, D. J., van Noorden, C. J. F., & Guchelaar, H.-J. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.06.010 · Cited by 300
Rizzo, M. A., Shome, K., Vasudevan, C., Stolz, D. B., Sung, T.-C., Frohman, M. A., Watkins, S. C., & Romero, G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.2.1131 · Cited by 297
Oncogenic Ras in tumour progression and metastasis
Giehl, K. (2005) · Biological Chemistry · doi:10.1515/bc.2005.025 · Cited by 287
Sebti, S. M., & Hamilton, A. D. (2000) · Oncogene · doi:10.1038/sj.onc.1204146 · Cited by 279
Self-citationPark, H.-J., Kong, D., Iruela-Arispe, L., Begley, U., Tang, D., & Galper, J. B. (2002) · Circulation Research · doi:10.1161/01.res.0000028149.15986.4c · Cited by 276
Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?
Cox, A. D., & Der, C. J. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00011-5 · Cited by 266
Self-citationRecent advances in understanding the mechanism of action of bisphosphonates
COXON, F., THOMPSON, K., & ROGERS, M. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.03.005 · Cited by 252
The Ras-related Protein Rheb Is Farnesylated and Antagonizes Ras Signaling and Transformation
Clark, G. J., Kinch, M. S., Rogers-Graham, K., Sebti, S. M., Hamilton, A. D., & Der, C. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.16.10608 · Cited by 177
Self-citationRegulation of Cyr61 gene expression by mechanical stretch through multiple signaling pathways
Tamura, I., Rosenbloom, J., Macarak, E., & Chaqour, B. (2001) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2001.281.5.c1524 · Cited by 90
Kazi, A., Xiang, S., Yang, H., Chen, L., Kennedy, P., Ayaz, M., Fletcher, S., Cummings, C., Lawrence, H. R., Beato, F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3399 · Cited by 81
Self-citationIchioka, F., Kobayashi, R., Katoh, K., Shibata, H., & Maki, M. (2008) · The FEBS Journal · doi:10.1111/j.1742-4658.2007.06230.x · Cited by 41
Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer
Cheng, D. K., Oni, T. E., Thalappillil, J. S., Park, Y., Ting, H.-C., Alagesan, B., Prasad, N. V., Addison, K., Rivera, K. D., Pappin, D. J., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2016904118 · Cited by 30
“This finding suggests that the interaction of RAF1 with KRAS depends on the GTP-bound state of KRAS rather than its localization and does not necessarily cause RAS pathway activation as has been previously reported (54).”
Metadata
- Authors
- Lerner, E. C., Qian, Y., Blaskovich, M. A., Fossum, R. D., Vogt, A., Sun, J., Cox, A. D., Der, C. J., Hamilton, A. D., & Sebti, S. M.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1995-11
- Volume
- 270
- Issue
- 45
- Pages
- 26802-26806
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2061234826
- Cited by
- 361
- References
- 35
- FWCI
- 6.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.